Photo credits
Why Buspirone Still Matters
Buspirone is the anxiolytic that treats generalized anxiety without doing any of the things benzodiazepines do to the patient. It doesn't sedate. It doesn't cloud cognition. It has no abuse potential, produces no tolerance, and has no withdrawal syndrome: it can be stopped cold with nothing more than a return of the underlying anxiety. It is FDA-approved for generalized anxiety disorder, costs pennies, and is one of the safest psychotropics in the formulary.
And yet it sits mostly unused, dismissed as weak. Two reasons account for that, and both deserve an honest look.
The first is onset. Buspirone does nothing acutely. It is not a rescue medication, it is not PRN, and a patient who takes one tablet expecting the melt-in-your-chest relief of a benzodiazepine will conclude, correctly, that "it did nothing," and never take it again. It works like an antidepressant works: on a two-to-four-week timescale, taken every day whether the patient feels anxious or not. Half the failures attributed to buspirone are really failures of patient education.
The second is effect size. In the pooled GAD meta-analysis (Hidalgo 2007, 21 double-blind placebo-controlled trials), buspirone's effect size is 0.17, against 0.36 for SSRIs and 0.38 for benzodiazepines. That number is real and you should know it. Read it next to the one randomized comparison that speaks to it: a reanalysis of 735 GAD patients given buspirone, a benzodiazepine or placebo found buspirone's four-week improvement similar to the benzodiazepine's in patients with no prior benzodiazepine use and in those whose use had ended a month or more earlier, and smaller in those who had stopped one within the past month. Ask about recent benzodiazepine use before you judge how buspirone is working.
Buspirone is a useful and safe anxiolytic, underused because it is slow and unglamorous, and its most common failure mode is educational rather than pharmacologic. Give it to the right patient, dose it correctly, take it with food, warn the patient it takes weeks, and insist it be taken every day rather than as needed, and you have a tool that spares GAD patients the dependence, sedation, and cognitive fog that benzodiazepines guarantee.
Buspirone was synthesized as a would-be antipsychotic and failed at that job entirely. It was rescued as an anxiolytic and approved in 1986 under the marketing line "a different kind of calm." The calm was different, all right. The market never quite forgave it for not being a benzodiazepine.
Part 1: Indications
FDA-Approved
- Generalized anxiety disorder (GAD): the one and only approved indication.
The Evidence-Based Clinical Picture
GAD, where it belongs. Buspirone is a reasonable choice for GAD, and it is arguably first-line when tolerability is the priority: the patient who cannot afford sexual side effects, who must not be sedated, who is at fall risk, who has a history of substance use, or who simply refuses anything with dependence potential. For most clinicians it is not the first drug for severe GAD; an SSRI or SNRI, with a larger effect size, usually is. It earns a place, either as an alternative to those agents or, very commonly, layered on top of them.
Buspirone's 0.17 looks damning next to the SSRIs' 0.36, and the gap is real. What it does not tell you is how one patient will do. In the 735-patient reanalysis, buspirone's four-week improvement matched a benzodiazepine's in everyone except the patients who had stopped a benzodiazepine within the past month. Don't confuse "modest on paper" with "doesn't work."
Antidepressant augmentation in MDD. This is buspirone's best-known off-label role, and the evidence is mixed. In STAR*D, citalopram plus buspirone (mean dose 40.9 mg/day) produced a 30.1% remission rate, nearly identical to citalopram plus bupropion (29.7%), with a median time to remission of about 5.4 weeks. That looks encouraging. But STAR*D's augmentation step was open-label and uncontrolled, and prior double-blind trials had shown buspirone augmentation no better than placebo. A large meta-analysis of treatment-resistant depression augmentation strategies (Nuñez 2022, 69 RCTs) found buspirone did not reach statistical significance, and it ranks below lithium, atypical antipsychotics, and thyroid augmentation. One bright spot: buspirone worked better in severe depression in a large randomized augmentation trial (Zhou 2015).
Reach for buspirone augmentation when tolerability is the governing concern: when the patient can't tolerate the weight gain or agitation of the usual augmenters, or when you need to avoid the metabolic cost of an antipsychotic. It is not a high-yield augmenter and should not be the first choice for straightforward treatment resistance. Use it when its clean side-effect profile is the point.
SSRI-induced sexual dysfunction. Because buspirone is pro-serotonergic at 5-HT1A but does not carry the sexual liability of SSRIs, it has been used to reverse SSRI-emergent sexual dysfunction. Evidence is weak: one controlled trial (n=47, doses ~47 mg/day) found significant improvement in women but not in men. A reasonable add-on to try; not a reliable fix.
SSRI-induced bruxism. Small literature, plausible mechanism, low-risk trial. Remember it when a patient reports jaw clenching on an SSRI.
Premenstrual dysphoric disorder (PMDD). Small controlled trials support 10–30 mg/day, dosed either continuously or across the two weeks before menses.
Aggression and irritability. Off-label but clinically established across dementia, traumatic brain injury, intellectual disability, ADHD, and oppositional defiant disorder. For TBI-related irritability and aggression, some experts use it first-line at doses up to 30 mg BID: its lack of sedation and cognitive burden is a decisive advantage in brain-injured patients.
Where Buspirone Does Not Work
- Panic disorder: no efficacy. Do not use it here. SSRIs/SNRIs are first-line.
- Social anxiety disorder: no efficacy, including as an augmentation strategy.
- OCD: inconclusive; not a serotonin-reuptake mechanism, and it doesn't deliver.
- Substance dependence: it may ease the anxiety of alcohol use disorder but does nothing for the addiction; cocaine and nicotine dependence trials are negative.
Buspirone is for chronic, generalized, worry-type anxiety in a patient who can wait a few weeks and take it daily. It is useless for panic attacks, useless for social phobia, and useless as a PRN. If the anxiety is paroxysmal or situational, this is the wrong drug.
Who Is the Ideal Candidate?
- The GAD patient for whom dependence, sedation, or falls are unacceptable: the elderly, patients with substance use histories, professionals who cannot be cognitively dulled, anyone a clinician would hesitate to hand a benzodiazepine.
- The patient with SSRI-induced sexual dysfunction worth salvaging.
- The patient who needs an anxiolytic layered onto an antidepressant without adding side-effect burden.
- The patient willing to be educated about slow onset and daily dosing: this willingness is the real inclusion criterion.
Part 2: Before You Start
This is one of the shortest pre-prescribing checklists in psychiatry, and that is part of the point.
- No baseline labs required. No renal panel, no LFTs, no ECG, no drug level. Buspirone needs no laboratory monitoring at baseline or ever.
- Screen for bipolar disorder. Buspirone can, rarely, precipitate a manic switch. Ask about prior mania/hypomania before starting, and if the patient is bipolar, use it with awareness and watch for mood elevation.
- Review the medication list for MAOIs and CYP3A4 interactions (see Part 6). This is the one screen that changes what you do.
- Set expectations about onset. The most important "pre-treatment" step is the conversation, covered in the education section below. Do it before the patient leaves with the prescription, not at the next visit.
With most drugs, the pre-start conversation is optional polish. With buspirone it is load-bearing. A patient who leaves the office expecting benzodiazepine-like relief will stop the drug within days and tell the next clinician "buspirone doesn't work for me." Two minutes of expectation-setting is the difference between a drug that works and a drug that "failed."
Part 3: How to Start and Dose
How to take itFDA labelAlways with food or always without, the same way each time. Food raises absorption.In practiceTwice daily, with food every dose. Split three ways only if a patient does better that way.
Interacting drugsCYP3A4 inhibitors and inducersFDA labelWith a potent CYP3A4 inhibitor, follow the dosage advice in the Drug Interactions section.In practiceStrong inhibitors: reduce the dose, for example to 2.5 mg twice daily. Inducers may need higher doses.
With MAOIsFDA labelAt least 14 days between an MAOI antidepressant and buspirone, in either direction.In practiceMAOI antidepressants: contraindicated (hypertensive reaction risk); allow a 14-day washout.
Older adultsFDA label(none)In practiceStart low and titrate gently. Reduced liver clearance and more interacting drugs argue for conservative dosing.
StoppingFDA label(none)In practiceNo taper needed; no withdrawal or rebound.
Formulation
Generic buspirone tablets, immediate-release. There is nothing fancier to reach for: no extended-release formulation is needed, and the drug is cheap.
Delayed Onset
Delayed onset is the defining fact about buspirone. Unlike a benzodiazepine, which relieves anxiety within the hour, buspirone behaves like an antidepressant: nothing acutely, then a gradual lift over two to four weeks of consistent daily dosing. There is no felt "kick," no sedation to notice, and no PRN use that accomplishes anything. This delayed, antidepressant-like onset, not any weakness in the underlying pharmacology, is the single biggest reason buspirone trials look unimpressive and the single biggest reason it fails in practice when the patient hasn't been warned.
BID vs TID: Dose It Twice Daily
The half-life is only 2–3 hours, which on paper argues for three-times-daily dosing. In practice, a controlled trial (Sramek 1999) found BID dosing equally effective, and BID is far easier to adhere to. Prescribe BID unless a specific patient does better split three ways. Adherence beats pharmacokinetic elegance every time. Because buspirone is typically dosed two to three times a day rather than once, the adherence burden is real. Name it to the patient up front.
Take It With Food, Every Dose
Taking buspirone with food increases absorption up to two-fold and directly reduces nausea. Food delays the peak but improves overall bioavailability. Every patient should hear it plainly: take it with a meal or a snack, every time, consistently. Consistency matters as much as the food itself: reproducible exposure day to day is the goal.
The Non-Negotiable Patient-Education Points
Say all of these out loud, and ideally write them down:
"This is not a PRN. Take it every single day, morning and evening, with food, whether or not you feel anxious." Buspirone taken as needed does nothing. This is the most common way it fails.
"It will not work right away. Give it two to four weeks. You may feel nothing for the first couple of weeks, and that's expected." Frame it like an antidepressant, not a tranquilizer.
"You will not feel a 'kick' or a wave of relief. This drug doesn't sedate you or give you that rewarding feeling. If it's working, you'll simply notice, over a few weeks, that you're less on edge."
"Every day, with food, and give it a month." If they remember nothing else, that sentence saves the prescription.
Dose Adjustments and Special Populations
- CYP3A4 interactions: buspirone is heavily CYP3A4-metabolized with low bioavailability. Strong 3A4 inhibitors (grapefruit juice, ketoconazole, itraconazole, ritonavir, nefazodone, erythromycin) sharply raise levels, so reduce the dose (e.g., 2.5 mg BID) and titrate cautiously. Diltiazem and verapamil raise levels more modestly, and the label leaves that adjustment to clinical assessment. Strong inducers (rifampin, carbamazepine) lower levels and may require higher doses.
- Renal impairment: reduce the dose; avoid in severe renal impairment. Hepatic impairment: reduce the dose; avoid in severe hepatic impairment.
- Geriatric: no specific adjustment beyond "start low"; the lack of sedation and dependence makes buspirone relatively attractive in older adults.
- Pediatric: efficacy not established in children (a pediatric GAD trial was negative).
Stopping and Switching
- Discontinuation: no taper required, because buspirone causes no physical dependence or withdrawal, a major advantage over benzodiazepines. It will not "cover" benzodiazepine withdrawal (no cross-tolerance).
Part 4: Side Effects and How to Manage Them
Buspirone is benign. Its side effects are few, mild, and mostly transient, and, more than that, it is defined as much by what it doesn't cause as by what it does.
The Side Effects It Does Have
Dizziness. The most characteristic. Usually mild and settles over the first couple of weeks at a stable dose.
Nausea. Common early, and largely preventable by taking the drug with food (which is why food is a standing instruction). If nausea appears, confirm the patient is dosing with meals before doing anything else.
Headache. Mild, common, transient.
Management: most of these are mild, dose-related, and self-limited. Take with food; reassure; wait 2–4 weeks at a stable dose before escalating. Escalating into early side effects is a common unforced error: give the drug time to settle first. If a patient cannot tolerate it, back down to the last comfortable dose and hold.
Manic switch (rare). Buspirone can, uncommonly, precipitate mania in patients with bipolar diathesis. Screen before starting; if the patient is bipolar or has a family history, monitor for mood elevation and be prepared to stop.
What Buspirone Does Not Cause
Contrast these directly with benzodiazepines, because this list is the reason buspirone exists:
| Effect | Benzodiazepines | Buspirone |
|---|---|---|
| Sedation | Yes | None |
| Cognitive/memory impairment | Yes | None |
| Fall risk | Yes (especially elderly) | Not established |
| Tolerance | Yes | None |
| Physical dependence | Yes | None |
| Withdrawal syndrome | Yes (can be dangerous) | None |
| Abuse potential | Yes (Schedule IV) | None (not scheduled) |
| Sexual dysfunction | Minimal | None (may even relieve SSRI-induced dysfunction) |
Everything in the right-hand column is a problem that doesn't have to be managed, a monitoring burden not carried, a conversation with a pharmacist or a family member never had. When weighing buspirone's modest effect size against a benzodiazepine's, weigh it against this column too.
Unlike its azapirone cousin gepirone, buspirone carries no QTc warning and needs no ECG monitoring, another point in its favor when cardiac safety matters.
Part 5: Monitoring
This is refreshingly short.
- No routine laboratory monitoring. No blood levels, no renal or hepatic panels, no ECG.
- Track symptoms, not labs. Use a standard anxiety (or, for augmentation, depression) rating scale at baseline and at follow-up, spaced at ≥4-week intervals, which conveniently matches the drug's onset timeline. Don't judge response before the drug has had its four weeks.
- In bipolar patients, monitor for emerging mood elevation at follow-up.
That's the entire monitoring protocol. The absence of a monitoring burden is, itself, a clinical feature: it makes buspirone deployable in settings and patients where a monitored drug isn't practical.
Part 6: Drug Interactions
Buspirone's interactions come from two facts: it is contraindicated with MAOIs, and it is a CYP3A4 substrate.
The Absolute One: MAOIs
Do not combine buspirone with an MAOI antidepressant. As a serotonergic agent, buspirone can precipitate serotonin syndrome and hypertensive reactions in combination with monoamine oxidase inhibitors. Observe the label's 14-day washout between an MAOI antidepressant and buspirone in either direction. The label also says not to start buspirone in a patient being treated with linezolid or intravenous methylene blue; if one of them is urgently needed in a patient already on buspirone, it says to stop buspirone promptly and monitor for serotonin syndrome. This is the one hard contraindication.
Because buspirone is serotonergic, the usual serotonin-syndrome caution applies when it is combined with other strongly serotonergic drugs; in routine SSRI co-prescription (the augmentation scenario) this is a theoretical rather than a practical concern at standard doses, but keep it in mind if a patient develops the syndrome's signs.
The CYP3A4 Axis: Dose Up or Dose Down
Buspirone is extensively metabolized by CYP3A4, and because it undergoes heavy first-pass metabolism, its levels swing widely when that enzyme is touched.
CYP3A4 inhibitors raise buspirone levels, use LOWER doses:
- Grapefruit juice: raises levels dramatically (4.3-fold peak concentration and 9.2-fold AUC in the study the label cites, on double-strength juice three times a day). Patients should avoid or strictly limit it. (Ask about it specifically: patients don't think of juice as a drug.)
- Fluvoxamine: a potent CYP inhibitor; a relevant trap since it's also used in anxiety.
- Nefazodone: strong 3A4 inhibitor.
- Azole antifungals (ketoconazole, itraconazole) and other strong 3A4 inhibitors (e.g., macrolides, some protease inhibitors): established pharmacology; when a patient is on one, start low and go slow.
CYP3A4 inducers lower buspirone levels, use HIGHER doses:
- Carbamazepine: the classic inducer; expect to need more buspirone, and expect levels to fall if it's added.
- Other strong inducers (rifampin, phenytoin, St. John's wort) behave the same way.
Inhibitors up the level, so dose down; inducers drop the level, so dose up. With a strong inhibitor on board, consider starting at the low end and titrating gently. With a strong inducer, don't be surprised when standard doses feel inert.
Theoretical, unresolved: buspirone's active metabolite (1-PP) is an alpha-2 antagonist, raising a theoretical interaction with alpha-2 agonists like clonidine and guanfacine. This is animal-study territory and unexplored in humans: know about it, but don't avoid the combination over it.
Part 7: Special Populations
The Elderly
This is one of buspirone's best use cases, and it deserves emphasis. The drugs most worth avoiding in older adults (benzodiazepines and their attendant sedation, cognitive impairment, and fall/fracture risk) are exactly the liabilities buspirone lacks. For an anxious older patient, buspirone offers anxiolysis without the confusion or the dependence that make benzodiazepines a Beers-criteria problem.
Practical approach: start low and titrate gently, as with any drug in the elderly, and be mindful that reduced hepatic clearance and polypharmacy (more chances for a 3A4 interaction) argue for conservative dosing. But the overall risk profile is favorable, and buspirone belongs high on the list for geriatric GAD.
Hepatic Impairment
Buspirone is cleared by the liver, and its levels rise substantially when hepatic function is impaired. Use with caution and reduced doses in mild-to-moderate hepatic impairment, and avoid it in severe hepatic impairment. This follows directly from its pharmacokinetics: heavy first-pass 3A4 metabolism means a compromised liver produces markedly higher exposure.
Renal Impairment
Buspirone exposure also increases in renal impairment. Use cautiously with dose reduction in moderate impairment, and avoid it in severe renal impairment (and in end-stage renal disease/dialysis). For patients with normal-to-mildly-reduced renal function, standard dosing is appropriate.
Pregnancy
The data are limited, and the honest answer is that solid human safety data don't exist. There is no established teratogenic signal, and buspirone has historically been regarded as relatively low-risk among anxiolytics (it carried the old FDA category B designation). That said, absence of a signal in limited data is not proof of safety. Weigh the risk of untreated maternal anxiety against limited reassurance data, prefer non-pharmacologic treatment where feasible, and if medication is needed, make the decision collaboratively. Don't manufacture certainty here; cautious, individualized judgment is the right posture.
Lactation
Data are sparse. Buspirone and its metabolites are presumed to pass into breast milk, and safety in the nursing infant is not established. If used during breastfeeding, do so cautiously and monitor the infant; where an alternative with better lactation data fits the clinical picture, prefer it.
Children and Adolescents
Off-label. Used in practice for aggression and irritability (in ADHD, ODD, intellectual disability, and TBI), where its lack of sedation and cognitive burden is attractive. Pediatric dosing for anxiety is not well established; individualize and start low.
Part 8: Discontinuation
This section is short because there is almost nothing to say, and that is the advantage.
Buspirone has no withdrawal syndrome, no rebound, and no discontinuation syndrome. It can be stopped abruptly. There is no taper to plan, no rebound anxiety to fear, no physiologic dependence to unwind. When a patient stops buspirone, the only thing that returns is the underlying anxiety the drug was treating; there is no additional withdrawal state layered on top.
Set this against the benzodiazepine reality: dose escalation over time, tolerance, and a withdrawal syndrome that ranges from uncomfortable to (with high doses) dangerous, requiring slow tapers measured in weeks to months. Buspirone simply does not do this. For patients at risk of getting "stuck" on a medication, buspirone is the anxiolytic that can be started, and stopped, without that worry.
Part 9: Buspirone vs the Alternatives
vs Benzodiazepines
This is the comparison that matters most, and it's the reason to know buspirone at all.
- Efficacy: comparable in the long term. In head-to-head trials against multiple benzodiazepines, buspirone held up, and patients switched from a benzodiazepine to buspirone did just as well over time. What buspirone lacks is the acute effect, the fast, felt relief.
- Onset: benzodiazepines work in an hour; buspirone works in weeks. This is buspirone's central handicap and the source of most of its bad reputation.
- Everything else: buspirone wins decisively: no sedation, no cognitive impairment, no tolerance, no dependence, no withdrawal, no abuse potential.
The switch is hard, and requires psychoeducation. Patients coming off benzodiazepines are the toughest group to start on buspirone: they miss the rewarding, sedating "kick," and buspirone doesn't provide it. Tell them plainly: "You're giving up that immediate rewarding effect. In exchange, you get anxiety control without the tolerance, the withdrawal, or the fog. But it takes a few weeks to get there, so be patient." Manage the transition deliberately; don't expect the benzo patient to be an easy convert.
The patient who stopped a benzodiazepine within the past month is buspirone's hardest customer. In the 735-patient reanalysis that group dropped out more often, reported more adverse events, and improved less than the patients given a benzodiazepine. Patients whose benzodiazepine use ended longer ago did as well as anyone. Don't read a rocky switch in a recent user as evidence the drug is weak in general.
vs SSRIs / SNRIs for GAD
- Effect size favors the antidepressants: SSRIs ~0.36 vs buspirone ~0.17.
- For moderate-to-severe GAD, an SSRI or SNRI is the more reliable monotherapy first-line.
- But buspirone earns its place as: (1) a first-line alternative when tolerability is the priority (no sexual dysfunction, no dependence, no cognitive effects); and (2) a common add-on to an antidepressant that is partially working, layered on without adding side-effect burden.
Note that vilazodone bundles an SSRI and buspirone's 5-HT1A partial agonism into a single molecule, and is still not clearly superior to either an SSRI or buspirone used alone.
Where Buspirone Sits, Summarized
Buspirone is rarely the first drug for severe GAD monotherapy, given the modest effect size. Its natural homes are: (1) GAD where tolerability trumps raw potency (the elderly, substance-use histories, patients who refuse dependence-forming drugs); (2) augmentation of a partially effective antidepressant; and (3) a benzodiazepine-sparing strategy in patients you don't want dependent. It is a step alongside or before pushing an antidepressant to maximum, and a permanent alternative for the tolerability-sensitive patient. It is not usually the monotherapy you lead with in severe illness.
Mechanism
Buspirone is an azapirone, and its principal action is partial agonism at the 5-HT1A serotonin receptor. By partially agonizing 5-HT1A (both presynaptic autoreceptors and postsynaptic sites), it modulates serotonergic tone in a way that reduces anxiety without the GABA-A potentiation that gives benzodiazepines their sedation, dependence, and abuse liability. This is the pharmacologic root of its entire clinical personality: the same 5-HT1A partial agonism appears in the antidepressant vilazodone and in several atypical antipsychotics (aripiprazole, brexpiprazole, cariprazine).
Secondary actions include mild D2 dopamine antagonism (a fingerprint of its failed antipsychotic origins) and poorly characterized noradrenergic effects. Its active metabolite, 1-PP, is an alpha-2 antagonist that may add to the anxiolytic effect, and is the theoretical basis for the unexplored alpha-2-agonist interaction.
The two facts to carry to the bedside: the 5-HT1A partial agonism is why it is serotonergic (hence the MAOI contraindication and the antidepressant-like slow onset), and the absence of GABA-A activity is why it is non-sedating, non-dependence-forming, and non-abusable. Everything clinically distinctive about buspirone traces to those two points.
The Bedside Cheat Sheet
Starting
- Generic IR buspirone, 7.5 mg BID (or 5 mg TID). Titrate to 15 mg BID over ~1 week.
- Then hold 2–4 weeks before judging efficacy or escalating.
- Typical effective range 20–30 mg/day divided; max 60 mg/day (90 mg/day off-label).
- Dose BID (equal to TID, better adherence). Take with food, every dose, consistently.
- No baseline labs. No ongoing labs. No ECG.
The three things every patient must hear
- Take it every day, with food: it is NOT a PRN.
- It takes 2–4 weeks: no acute relief.
- No "kick." If it works, you'll just feel less on edge over weeks.
What it treats
- GAD (FDA-approved; first-line when tolerability is the priority).
- Antidepressant augmentation (modest/mixed evidence; use when tolerability matters).
- Off-label: PMDD (10–30 mg/day), SSRI sexual dysfunction, SSRI bruxism, aggression/irritability (up to 30 mg BID, incl. TBI).
- Does NOT work: panic disorder, social anxiety, OCD, substance dependence.
Side effects
- Dizziness, nausea (take with food), headache: mild, transient. Reassure and wait.
- NONE of: sedation, cognitive impairment, tolerance, dependence, withdrawal, abuse, sexual dysfunction.
- Rare: manic switch (screen for bipolar).
Interactions
- MAOI antidepressants = contraindicated (serotonin syndrome; 14-day washout). No new start on linezolid or IV methylene blue.
- CYP3A4 substrate: inhibitors (grapefruit juice, fluvoxamine, nefazodone, azoles) → dose DOWN; inducers (carbamazepine, rifampin) → dose UP.
Special populations
- Elderly: a strong choice, anxiolysis without sedation or dependence.
- Hepatic impairment: caution/reduce; avoid if severe. Renal impairment: caution/reduce; avoid if severe.
- Pregnancy/lactation: limited data, no clear signal, individualize.
Stopping
- No taper needed. No withdrawal. Stop whenever.
Buspirone will never feel dramatic. It doesn't rescue a panic attack, it doesn't produce a moment of relief the patient can point to, and its effect size on paper is small. That is why it's underprescribed and undervalued. It is a chronic anxiolytic that spares the patient every liability that makes benzodiazepines a long-term problem: no sedation, no cognitive fog, no dependence, no withdrawal, no abuse. It asks almost nothing of the prescriber (no labs, no ECG, no taper) and only one thing of the patient: take it every day, with food, and give it a month. Meet that condition and it does its job. For the right GAD patient, especially the older one, the one you don't want dependent, the one who can't afford to be dulled, buspirone is the safe choice rather than a weak one.